| 1.65 0 (0%) | 12-31 19:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.92 | 1-year : | 2.25 |
| Resists | First : | 1.64 | Second : | 1.92 |
| Pivot price | 1.64 | |||
| Supports | First : | 1.62 | Second : | 1.61 |
| MAs | MA(5) : | 1.64 | MA(20) : | 1.64 |
| MA(100) : | 1.64 | MA(250) : | 3.11  |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 100 | D(3) : | 100 |
| RSI | RSI(14): 21.9 | |||
| 52-week | High : | 8.8 | Low : | 1.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LBPS ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 93 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.65 - 1.66 | 1.66 - 1.67 |
| Low: | 1.59 - 1.6 | 1.6 - 1.61 |
| Close: | 1.63 - 1.65 | 1.65 - 1.67 |
4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.
Thu, 10 Nov 2022
Live Biotherapeutic Product (LBP) Market to reach over USD 2.60 billion by the year 2030- Exclusive Report by ... - openPR
Thu, 07 Jul 2022
Live Biotherapeutic Product (LBP) Market worth $ 2.60 billion by 2030 - Exclusive Report by InsightAce Analytic - PR Newswire
Wed, 23 Mar 2022
4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and ... - Business Wire
Fri, 11 Feb 2022
Does the Gartner Hype Cycle explain the ebb and flow of the multi-billion dollar human microbiome industry? - Proactive Investors UK
Thu, 04 Nov 2021
Developing and delivering live biotherapeutic products - European Pharmaceutical Review
Mon, 29 Mar 2021
Firm Advises 4D pharma on Merger with Longevity Acquisition Corporation and Nasdaq ADS Listing - Wilson Sonsini
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 1.679e+007 (%) |
| Held by Institutions | 2.4 (%) |
| Shares Short | 65 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.545e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 125.6 % |
| Return on Equity (ttm) | -42.7 % |
| Qtrly Rev. Growth | 718000 % |
| Gross Profit (p.s.) | -3.67 |
| Sales Per Share | -27.37 |
| EBITDA (p.s.) | 219572 |
| Qtrly Earnings Growth | -4.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.07 |
| Price to Cash Flow | 3.06 |
| Dividend | 0 |
| Forward Dividend | 58610 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|